REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$11.69 USD
-0.81 (-6.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.80 +0.11 (0.94%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
RGNX 11.69 -0.81(-6.48%)
Will RGNX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RGNX
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Other News for RGNX
JMP Securities healthcare analysts hold an analyst/industry conference call
REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
REGENXBIO names Mitchell Chan as finance chief
Regenxbio names Mitchell Chan as CFO, succeeding Vit Vasista
RegenXBio Appoints New EVP and CFO Amidst Key Developments